Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
LumiraDx Limited operates as a point of care diagnostics company.
The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers.
It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care.
The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions.
Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease.
The company is headquartered in London, the United Kingdom.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 10, 23 | -0.15 Increased by +30.19% | -0.14 Decreased by -6.00% |
| Aug 24, 23 | -0.16 Increased by +48.39% | -0.13 Decreased by -21.21% |
| May 16, 23 | -0.13 Increased by 0.00% | -0.14 Increased by +7.14% |
| Mar 21, 23 | -0.12 Decreased by -50.00% | -0.19 Increased by +37.04% |
| Nov 9, 22 | -0.21 Decreased by -31.25% | -0.25 Increased by +16.00% |
| Aug 18, 22 | -0.31 Decreased by -30.36% | -0.25 Decreased by -22.00% |
| May 11, 22 | -0.13 Decreased by -167.15% | -0.05 Decreased by -139.41% |
| Mar 10, 22 | -0.08 Increased by +69.23% | -0.17 Increased by +52.07% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 21.00 M - | -49.74 M - | Decreased by -236.80% - |
| Mar 31, 23 | 22.17 M - | -44.21 M - | Decreased by -199.39% - |
| Dec 31, 22 | 41.12 M - | -100.60 M - | Decreased by -244.66% - |
| Sep 30, 22 | 42.22 M - | -143.48 M - | Decreased by -339.86% - |